Related Experiment Video
Updated: Dec 27, 2025

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
Published on: September 27, 2024
Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer
Feng Jiao1, Ting Han1, Cuncun Yuan2
11Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Road, Shanghai, 200127 China.
Background:
The bromodomain and extra-terminal domain (BET) family of proteins, especially BRD4 play an important role in epigenetic regulation, and are essential for cell survival and also are promising anticancer targets. This study aims to analyze the effect of BRD4 on the cell growth and progression of pancreatic cancer and novel mechanisms involved.
Methods:
Expression of BRD4 in pancreatic cancer and paired adjacent noncancerous tissues from 76 patients was analyzed by western blotting, immunohistochemistry, and real time PCR. Its correlation with the clinicopathological characteristics and prognosis of pancreatic cancer patients was analyzed. The effects of BRD4 on the cell proliferation were detected by colony formation assay and sulforhodamine B assay. Migration and invasion were determined by Transwell assays, and the effect of BRD4 on subcutaneous tumor formation was verified in nude mice. Cell cycle analysis was detected by flow cytometry. The potential downstream targets of BRD4 and related molecular mechanisms were clarified by RNA sequencing, chromatin immunoprecipitation and dual luciferase reporter assay.
Results:
BRD4 was overexpressed in pancreatic cancer. Biological results showed that BRD4 functioned as tumor promoter, facilitated cell proliferation, migration and invasion in vitro and in vivo. Further, caveolin-2 was selected as the downstream gene of BRD4 by RNA sequencing. Caveolin-2 overexpression can partially reverse the decreased cell growth ability caused by BRD4 knockdown, but did not affect cell migration and invasion. Chromatin immunoprecipitation assay and dual luciferase reporter assay revealed BRD4 could bind to the promoter region of caveolin-2 and upregulate caveolin-2 expression. Clinical data further indicated a positive correlation between BRD4 and caveolin-2 expression. BRD4 (high)/caveolin-2 (high) correlated with shorter overall survival of patients with pancreatic cancer. Multivariate analysis revealed that both BRD4 and caveolin-2 were independent factors.
Conclusions:
Our findings reveal the oncogenic effects of BRD4 in pancreatic cancer and elucidate a possible mechanism by which BRD4 and caveolin-2 act to enhance cell growth. Targeting the BRD4-caveolin-2 interaction by development of BET inhibitors will be a therapeutic strategy for pancreatic cancer.
Insights
Bromodomain and extra-terminal domain (BET) protein BRD4 promotes pancreatic cancer growth and progression by upregulating caveolin-2. Targeting this interaction offers a potential therapeutic strategy for pancreatic cancer.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Bromodomain and extra-terminal domain (BET) proteins, particularly BRD4, are crucial for epigenetic regulation and cell survival.
- BRD4 is a promising target for anticancer therapies.
- Pancreatic cancer progression involves complex molecular mechanisms that require further elucidation.
Purpose of the Study:
- To investigate the role of BRD4 in pancreatic cancer cell growth and progression.
- To identify novel mechanisms underlying BRD4's function in pancreatic cancer.
- To explore the potential of targeting BRD4 as a therapeutic strategy.
Main Methods:
- Western blotting, immunohistochemistry, and real-time PCR were used to analyze BRD4 expression in patient tissues.
- In vitro assays (colony formation, sulforhodamine B, Transwell) and in vivo studies in nude mice assessed BRD4's effects on cell proliferation, migration, and invasion.
- RNA sequencing, ChIP, and dual luciferase reporter assays identified downstream targets and molecular mechanisms.
Main Results:
- BRD4 was overexpressed in pancreatic cancer and promoted cell proliferation, migration, and invasion in vitro and in vivo.
- Caveolin-2 was identified as a downstream target of BRD4, with BRD4 binding to its promoter region and upregulating its expression.
- High expression of both BRD4 and caveolin-2 correlated with shorter patient survival, and both were identified as independent prognostic factors.
Conclusions:
- BRD4 exhibits oncogenic effects in pancreatic cancer, partly through the upregulation of caveolin-2, enhancing cell growth.
- The BRD4-caveolin-2 interaction represents a potential therapeutic target for pancreatic cancer.
- Development of BET inhibitors targeting the BRD4-caveolin-2 interaction could be a viable treatment strategy.
More Related Videos
09:52A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
Published on: September 20, 2016
06:24Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Abnormal Proliferation
Negative Regulator Molecules